Table 4: Combined expressions of VEGF-C and CNTN-1 associated with clinicopathologic characteristics ( /%).

CharacteristicBoth high expressiona
( )
Both non high expressionb ( ) value

Age (ys)0.761
  ≧6016/61.512/66.7
  <6010/38.56/33.3
Gender0.323
 Male20/76.911/61.1
 Female6/23.17/38.9
Tumor size0.234
  ≧5 cm17/65.48/47.1
  <5 cm9/34.69/52.9
Tumor location0.292
 Upper10/38.43/16.7
 Middle8/30.87/38.9
 Lower8/30.88/44.4
Lauren’s classification0.395
 Intestinal14/53.812/66.7
 Diffuse12/46.26/33.3
TNM stage0.023
  I + II5/19.210/55.6
  III + IV21/80.88/44.4
Vascular invasion0.325
  (+)15/57.713/72.2
  (−)11/42.35/27.8
Serosa invasion0.014
  (+)9/34.613/72.2
  (−)17/63.45/27.8
Lymphatic invasion0.005
  (+)25/96.211/61.1
  (−)1/3.87/38.9
Lymph node metastasis0.013
  (+)25/96.212/66.7
  (−)1/3.86/33.3
Lymph node metastatic ratio0.395
  ≧20%12/46.26/33.3
  <20%14/53.812/66.7
Average survival (mean ± SD) (months)16.8 ± 3.823.2 ± 5.00.032

Note: “a”: indicates that expression of both VEGF-C and CNTN-1 in tumor cells is high. “b”: indicates samples with combined expressions of VEGF-C and CNTN-1 except those of both high expressions.